Literature DB >> 26170977

In vitro study on shRNA-mediated reduction of testis developmental related gene 1 expression and its effects on the proliferation, invasion and apoptosis of NTERA-2 cells.

Y U Gan1, Jianfu Yang1, Yong Wang1, Zhengyu Tan1, Xianzhen Jiang1, Yuxin Tang1.   

Abstract

Testis developmental related gene 1 (TDRG1) is a novel human testis-specific gene. TDRG1 is differentially expressed in cancerous tissue compared with normal testicular tissue and demonstrates a unique expression pattern in normal testes; therefore, this gene may be involved in the occurrence and development of testicular germ cell tumors (TGCT). In the present study, the expression level of TDRG1 was downregulated in human TGCT NTERA-2 cells by RNA interference (RNAi) in order to investigate the association between TDRG1 and TGCT. The TDRG1 mRNA and protein expression levels in NTERA-2 cells were significantly inhibited following transfection with specific RNAi plasmids. The ability to proliferate (inhibited by 15.4% at day 3 and 26.1% at day 5; P<0.001) and invade (reduced by 49.1%; P=0.01) in vitro was suppressed in cells in which the expression level of TDRG1 was reduced, and a corresponding increase in the apoptotic potential was observed (the early apoptotic potential and total apoptotic potential were increased by 75%; P=0.019 and 54.8%; P=0.009, respectively). The results of the present study indicated that the biological behavior of NTERA-2 cells is associated with TDRG1 expression levels, and that this gene may be a novel target candidate in the treatment of TGCT.

Entities:  

Keywords:  NTERA-2; TDRG1; cell biological behavior; in vitro; siRNA

Year:  2015        PMID: 26170977      PMCID: PMC4486812          DOI: 10.3892/ol.2015.3219

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

3.  [Construction of TDRG1 shRNA expression vector and interfering effect of TDRG1 shRNA expression vector on NTERA-2 cells].

Authors:  Shenglin Peng; Jianfu Yang; Houyang Chen; Xiaoliang Guo; Dongjie Li; Huabo Zhou; Yu Gan; Xianzhen Jiang; Yuxin Tang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2012-10

4.  International trends in the incidence of testicular cancer, 1973-2002.

Authors:  Victoria M Chia; Sabah M Quraishi; Susan S Devesa; Mark P Purdue; Michael B Cook; Katherine A McGlynn
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

5.  [Preparation and identification of monoclonal antibody against human testis development related gene 1].

Authors:  Jiaming Wen; Xianzhen Jiang; Yuxin Tang; Jianfu Yang; Houyang Chen; Zhizhong Liu
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2010-03

6.  [Establishment and characterization of a new human testicular germ cell tumor cell line (TCam-2)].

Authors:  Y Mizuno; A Gotoh; S Kamidono; S Kitazawa
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1993-07

7.  TCam-2 but not JKT-1 cells resemble seminoma in cell culture.

Authors:  D Eckert; D Nettersheim; L C Heukamp; S Kitazawa; K Biermann; H Schorle
Journal:  Cell Tissue Res       Date:  2007-11-15       Impact factor: 5.249

8.  Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro.

Authors:  P W Andrews; I Damjanov; D Simon; G S Banting; C Carlin; N C Dracopoli; J Føgh
Journal:  Lab Invest       Date:  1984-02       Impact factor: 5.662

9.  Expression of Fas and Fas ligand in human testicular germ cell tumours.

Authors:  E Baldini; S Ulisse; E Marchioni; A Di Benedetto; G Giovannetti; E Petrangeli; S Sentinelli; R P Donnorso; M G Reale; M Mottolese; L Gandini; A Lenzi; M D'Armiento
Journal:  Int J Androl       Date:  2007-10-03

10.  JKT-1 is not a human seminoma cell line.

Authors:  Jeroen de Jong; Hans Stoop; Ad J M Gillis; Ruud J H L M van Gurp; Ellen van Drunen; H Berna Beverloo; Yun-Fai Chris Lau; Dominik T Schneider; Jon K Sherlock; John Baeten; Shingo Hatakeyama; Chikara Ohyama; J Wolter Oosterhuis; Leendert H J Looijenga
Journal:  Int J Androl       Date:  2007-08
View more
  5 in total

1.  TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway.

Authors:  Yu Gan; Yong Wang; Zhengyu Tan; Jun Zhou; Riko Kitazawa; Xianzhen Jiang; Yuxin Tang; Jianfu Yang
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

2.  TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway.

Authors:  Yong Wang; Yu Gan; Zhengyu Tan; Jun Zhou; Riko Kitazawa; Xianzhen Jiang; Yuxin Tang; Jianfu Yang
Journal:  Onco Targets Ther       Date:  2016-01-20       Impact factor: 4.147

3.  The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer.

Authors:  Hui Jiang; Min Liang; Yanqiong Jiang; Ting Zhang; Kexin Mo; Suwen Su; Aiping Wang; Yongyi Zhu; Guanqun Huang; Rujian Zhou
Journal:  Cancer Cell Int       Date:  2019-05-31       Impact factor: 5.722

4.  Knockdown of lncRNA TDRG1 Inhibits Tumorigenesis in Endometrial Carcinoma Through the PI3K/AKT/mTOR Pathway.

Authors:  Ruimei Sun; Xiujiang Sun; Hua Liu; Peirui Li
Journal:  Onco Targets Ther       Date:  2019-12-11       Impact factor: 4.147

5.  The rs8506 TT Genotype in lincRNA-NR_024015 Contributes to the Risk of Sepsis in a Southern Chinese Child Population.

Authors:  Jinqing Li; Huazhong Zhou; Bing Wei; Di Che; Yufen Xu; Lei Pi; Lanyan Fu; Jie Hong; Xiaoqiong Gu
Journal:  Front Public Health       Date:  2022-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.